TRCT
ELDN icon

Tower Research Capital (TRC)’s Eledon Pharmaceuticals ELDN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1K Sell
4,249
-23,102
-84% -$54.4K ﹤0.01% 3757
2025
Q4 		$41.3K Buy
27,351
+16,682
+156% +$39.7K ﹤0.01% 2572
2025
Q3 		$27.6K Buy
10,669
+10,666
+355,533% +$31.2K ﹤0.01% 3021
2025
Q2 		$8 Sell
3
-12,475
-100% -$37.4K ﹤0.01% 5231
2025
Q1 		$42.3K Buy
12,478
+4,534
+57% +$18.7K ﹤0.01% 2340
2024
Q4 		$32.7K Buy
7,944
+6,412
+419% +$25.3K ﹤0.01% 2841
2024
Q3 		$3.81K Sell
1,532
-15,426
-91% -$41.3K ﹤0.01% 4767
2024
Q2 		$44.8K Buy
16,958
+11,284
+199% +$26.9K ﹤0.01% 3189
2024
Q1 		$11.7K Buy
5,674
+38
+0.7% +$68 ﹤0.01% 3541
2023
Q4 		$10.1K Sell
5,636
-2,807
-33% -$3.9K ﹤0.01% 4286
2023
Q3 		$11.6K Sell
8,443
-3,007
-26% -$4.01K ﹤0.01% 3979
2023
Q2 		$15.7K Buy
11,450
+5,199
+83% +$10.8K ﹤0.01% 3616
2023
Q1 		$15K Buy
6,251
+4,353
+229% +$11.7K ﹤0.01% 3780
2022
Q4 		$4K Buy
1,898
+1,258
+197% +$3.11K ﹤0.01% 4998
2022
Q3 		$1K Sell
640
-395
-38% -$1.26K ﹤0.01% 5762
2022
Q2 		$3K Sell
1,035
-291
-22% -$888 ﹤0.01% 5365
2022
Q1 		$5K Sell
1,326
-730
-36% -$2.83K ﹤0.01% 5039
2021
Q4 		$9K Buy
+2,056
New +$10.4K ﹤0.01% 4683
2021
Q3 		– Sell
-643
Closed -$5K – 5852
2021
Q2 		$5K Buy
+643
New +$6.07K ﹤0.01% 4702
2021
Q1 		– Sell
-2,598
Closed -$40K – 5466
2020
Q4 		$40K Buy
2,598
+1,341
+107% +$25.6K ﹤0.01% 3319
2020
Q3 		$21K Buy
+1,257
New +$12.4K ﹤0.01% 3848
2018
Q2 		– Sell
-16
Closed -$1K – 3740
2018
Q1 		$1K Sell
16
-68
-81% -$5.01K ﹤0.01% 3056
2017
Q4 		$6K Sell
84
-227
-73% -$17.1K ﹤0.01% 2808
2017
Q3 		$29K Buy
311
+267
+607% +$22.2K ﹤0.01% 2464
2017
Q2 		$5K Sell
44
-123
-74% -$12.5K ﹤0.01% 1974
2017
Q1 		$23K Buy
+167
New +$24.5K ﹤0.01% 1208
2016
Q4 		– Sell
-98
Closed -$24K – 3943
2016
Q3 		$24K Buy
98
+78
+390% +$28.5K ﹤0.01% 1505
2016
Q2 		$17K Buy
+20
New +$22.1K ﹤0.01% 2370
2016
Q1 		– Sell
-7
Closed -$6.87K – 4301
2015
Q4 		$10K Buy
+7
New +$12.2K ﹤0.01% 2098
2015
Q3 		– Sell
-3
Closed -$6.18K – 4176
2015
Q2 		$7K Sell
3
-12
-80% -$23.2K ﹤0.01% 2987
2015
Q1 		$27K Buy
+15
New +$33.1K ﹤0.01% 1992
2014
Q4 		– Sell
-1
Closed -$3K – 4163
2014
Q3 		$3K Buy
+1
New +$2.84K ﹤0.01% 3596

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Tower Research Capital (TRC)'s ELDN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Eledon Pharmaceuticals (ELDN) stake by 84% in Q1 2026, selling an estimated $54.4K and leaving 4,249 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3757.

Tower Research Capital (TRC) first reported a position in ELDN in Q3 2014 and has held it in 32 quarters since. The position peaked at $44.8K in Q2 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Tower Research Capital (TRC) held 4,249 shares of Eledon Pharmaceuticals worth $13.1K as of Q1 2026.
  • Tower Research Capital (TRC) sold 23,102 Eledon Pharmaceuticals shares in Q1 2026, an estimated $54.4K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3757 holding.
  • Tower Research Capital (TRC) first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 32 quarters since.
  • Tower Research Capital (TRC)'s Eledon Pharmaceuticals position peaked at $44.8K in Q2 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.